Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics


CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.

Potential Commercial Applications: Competitive Advantages:
  • Diagnostic tests assessing active Lethal Factor in a sample
  • Anthrax neutralizing therapeutics and vaccines for B. anthracis
  • Biodefense, biosecurity
 
  • Potentially faster, lower-input assay compared to current Edema Factor detection methods
  • Easily adaptable for high-throughput screening of numerous specimens


Development Stage:
  • Early-stage
  • In vitro data available


Related Invention(s):
E-158-2013/2
E-167-2013/0
E-196-2013/0
E-203-2013/0
E-474-2013/0


Inventors:

Conrad Quinn (CDC)  ➽ more inventions...

Anne Boyer (CDC)  ➽ more inventions...

Jason Goldstein (CDC)  ➽ more inventions...

Dennis Bagarozzi (CDC)  ➽ more inventions...


Intellectual Property:
US Application No. 61/699,738
PCT Application No. PCT/US2013/059179
US Application No. 14/427,329

Publications:
Boyer AE, et al. PMID 17929949

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-210-2013/0
Updated: Mar 3, 2017